Company Description

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.

The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen.

The company was founded in 2014 and is based in Boston, Massachusetts.

Adicet Bio, Inc.

Country	United States
Founded	1947
Industry	Biotechnology
Sector	Healthcare
Employees	102
CEO	Chen Schor

Contact Details

Address: 131 Dartmouth Street, 3rd Floor Boston, Massachusetts 02116 United States
Phone	650 503 9095
Website	adicetbio.com

Stock Details

Ticker Symbol	ACET
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001720580
CUSIP Number	007002207
ISIN Number	US0070022076
Employer ID	81-3305277
SIC Code	2834

Key Executives

Name	Position
Chen Schor BA, CPA, M.B.A.	Chief Executive Officer, President and Director
Dr. Blake Aftab Ph.D.	Senior Vice President and Chief Scientific Officer
Dr. Lloyd Klickstein M.D., Ph.D.	Interim Chief Medical Officer and Director
Brian Nicholas Harvey M.B.A.	Chief Financial Officer
Dr. Donald Healey Ph.D.	Chief Technology Officer
Amy Locke	Chief Human Resource Officer

Latest SEC Filings

Date	Type	Title
Sep 28, 2026	8-K	Current Report
Sep 8, 2026	8-K	Current Report
Sep 1, 2026	8-K	Current Report
Aug 14, 2026	SCHEDULE 13G/A	Filing
Aug 5, 2026	10-Q	Quarterly Report
Aug 5, 2026	8-K	Current Report
Jun 18, 2026	8-K	Current Report
May 20, 2026	10-K/A	[Amend] Annual report
May 15, 2026	SCHEDULE 13G/A	Filing
May 13, 2026	S-8 POS	Securities to be offered to employees in employee benefit plans, post-effective amendments

View All SEC Filings